Practice Test Geeks(RAC) Regulatory Affairs Certification Practice Test
← All RAC Flashcard Decks

Regulatory Strategic Planning Flashcards

7 cards from real RAC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Regulatory Strategic Planning flashcards as text

  1. A regulatory affairs team is considering whether to use a Real-World Evidence (RWE) study to support a label expansion. The primary regulatory challenge with RWE is:

    Answer: Demonstrating that the real-world data are fit for purpose and meet standards for reliability and relevance

    The primary challenge with RWE is demonstrating data fitness for purpose — the data must be of sufficient quality and relevance to support the specific regulatory decision.

  2. When building a regulatory strategy for a pediatric indication, which US regulatory requirement must be considered from early development?

    Answer: The Pediatric Research Equity Act (PREA) may require pediatric studies as part of the application

    Under PREA, sponsors of new drugs and biologics for adult indications must assess the product in pediatric populations unless a waiver or deferral is granted.

  3. A company is planning a regulatory strategy for a digital health product incorporating AI/ML. The most relevant FDA regulatory framework to consider is:

    Answer: FDA's action plan for AI/ML-based Software as a Medical Device (SaMD)

    FDA's AI/ML-based SaMD action plan and the predetermined change control plan framework are specifically designed for adaptive AI/ML technologies in medical devices.

  4. Which element is most essential in a regulatory submission timeline when multiple global agencies are targeted?

    Answer: Identifying agency-specific requirements and building in time for translations and local data supplements

    Global submissions require mapping agency-specific requirements, local data needs, and translation timelines to create a realistic multi-agency submission schedule.

  5. In regulatory strategic planning, a 'target product profile' (TPP) serves as:

    Answer: A prospective summary of the desired characteristics of a product that guides development decisions

    The TPP is a prospective, dynamic document that articulates the intended clinical profile of the product and serves as a benchmark to align development and regulatory strategy.

  6. Under EU regulations, which procedure allows a company to obtain a single marketing authorization valid across all EU member states?

    Answer: Centralized Procedure

    The Centralized Procedure, managed by EMA and CHMP, results in a single EU-wide marketing authorization valid in all EU member states plus EEA countries.

  7. A strategic decision to seek 'rolling review' in the US allows a sponsor to:

    Answer: Submit completed sections of the NDA/BLA for review as they are finished, before the full dossier is complete

    Rolling review allows sponsors with Fast Track designation to submit completed NDA/BLA modules for FDA review on a rolling basis rather than waiting until the entire application is complete.